Immunogen Story

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:4em;'>IM</div>
IMGN -- USA Stock  

USD 8.64  0.14  1.59%

ImmunoGen Tangible Asset Value is quite stable at the moment as compared to the past year. The company's current Tangible Asset Value is estimated at 277.11 Million. Working Capital is expected to rise to about 181.5 M this year, although the value of Net Income Per Employee will most likely fall to (1.6 M). The goal of this thesis is to give institutional investors our take on ImmunoGen future value. We will inspect the reasons why it could be a game-changer for ImmunoGen institutional investors.
Published over a week ago
View all stories for Immunogen | View All Stories
Are ImmunoGen (NASDAQ:IMGN) institutional investors starting to hold back?
Over 74.0% of ImmunoGen shares are owned by institutional investors. Institutional ownership of ImmunoGen refers to the amount of ImmunoGen equity owned by mutual funds, pension funds, insurance companies, investment firms, foundations, or other large entities that manage money on behalf of others. Check out our latest analysis of ImmunoGen, including its current ownership diagnostics.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Immunogen. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Immunogen

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Immunogen's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Immunogen in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Immunogen. Your research has to be compared to or analyzed against Immunogen's peers to derive any actionable benefits. When done correctly, Immunogen's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Immunogen.

How important is Immunogen's Liquidity

Immunogen financial leverage refers to using borrowed capital as a funding source to finance Immunogen ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Immunogen financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Immunogen's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Immunogen, but it might be worth checking our own buy vs. sell analysis

Acquisition by Lentini Renee of 80800 shares of Immunogen subject to Rule 16b-3

Legal trades by Immunogen insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Immunogen insider trading alert for grant of common stock (right to buy) by Lentini Renee, V.P.-Fin. Prin. Acctg. Off., on 9th of February 2021. This event was filed by Immunogen Inc with SEC on 2021-02-09. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking it down a bit more

ImmunoGen shows above-average downside volatility for the selected time horizon. We advise investors to inspect ImmunoGen further and ensure that all market timing and asset allocation strategies are consistent with the estimation of ImmunoGen future alpha.

Margin Breakdown

Operating Margin(49.61)
EBITDA Margin(1.51)
Gross Margin0.89
Profit Margin(1.57)

Will ImmunoGen latest rise continue?

Kurtosis is down to 0.99. It may entail a possible volatility slide. ImmunoGen shows above-average downside volatility for the selected time horizon. We advise investors to inspect ImmunoGen further and ensure that all market timing and asset allocation strategies are consistent with the estimation of ImmunoGen future alpha.

Our Final Takeaway

Whereas some firms under the biotechnology industry are still a bit expensive, ImmunoGen may offer a potential longer-term growth to institutional investors. Taking everything into account, as of the 13th of February 2021, we believe ImmunoGen is currently undervalued. It slowly supersedes the market and projects very low probability of distress in the next two years. Our primary 30 days buy-hold-sell advice on the company is Strong Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Immunogen. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com